Oncology News

CHICAGO — In a randomized phase 2 trial, treatment with Nexavar plus hepatic arterial infusion chemotherapy with cisplatin yielded better results vs. treatment with Nexavar alone for patients with advanced hepatocellular carcinoma, according to a poster presented at the ASCO Annual Meeting.

CHICAGO — In an ongoing phase 2 clinical trial, Inlyta and transarterial chemoembolization therapy was safe and yielded high response rates in Chinese patients with hepatocellular carcinoma, according to a poster presented at the ASCO Annual Meeting.

Exalenz Biosciences announced a clinical trial is underway to investigate whether its BreathID test is useful in diagnosing hepatocellular carcinoma, according to a press release from the manufacturer.

CHICAGO — In a phase 2 trial, hypofractionated proton beam therapy was effective in improving overall survival in patients with intrahepatic cholangiocarcinoma, according to a poster presented at the ASCO Annual Meeting.

CHICAGO — Nivolumab appeared safe and effective for the treatment of patients with advanced hepatocellular carcinoma, according to interim study results presented at the ASCO Annual Meeting.

Delcath Systems, Inc. announced the intrahepatic cholangiocarcinoma study cohort of its global phase 2 trial of Melphalan/HDS therapy for the treatment of unresectable hepatocellular carcinoma is now enrolling patients, according to a press release.

Donations after brain and cardiac death allografts did not increase a patient’s likelihood of developing hepatocellular carcinoma recurrence after liver transplantation, according to newly published data in the American Journal of Transplantation.

Conditional survival estimates may provide more accurate quantitative information than OS about the changing survival probability for patients undergoing liver resection for intrahepatic cholangiocarcinoma, according to study results.

Taiwanese patients with chronic hepatitis B virus infection and newly diagnosed diabetes had an increased risk for hepatocellular carcinoma over time, according to study findings.

Can-Fite BioPharma Ltd. announced the European Medicines Agency approved a phase 2 clinical trial for CF102, a potential drug treatment for hepatocellular carcinoma, and has already dosed its first patient in Europe, according to a press release from the manufacturer.